[1] KREUTER J. Nanoparticles--a historical perspective[J]. Int J Pharm，2007，331(1)：1-10. [2] IBRAHIM A，COUVREUR P，SPEISER P，et al. New magnetic drug carrier[J]. J Pharm Pharmacol，1983，35(1)：59-61. [3] OLIVIER J C. Drug transport to brain with targeted nanoparticles[J]. Neuro Rx，2005，2(1)：108-119. [4] KREUTER J. Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain[J]. J Nanosci Nanotechnol，2004，4(5)：484-488. [5] KREUTER J. Nanoparticulate systems for brain delivery of drugs[J]. Adv Drug Deliv Rev，2001，47(1)：65-81. [6] KREUTER J，SHAMENKOV D，PETROV V，et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier[J]. J Drug Target，2002，10(4)：317-325. [7] SUZUKI T，ZAIMA C，MORIKI Y，et al. P-glycoprotein mediates brain-to-blood efflux transport of buprenorphine across the blood-brain barrier[J]. J Drug Target，2007，15(1)：67-74. [8] BAO S Y. Blood-brain barrier A barrier in front of neuroscientists [J]. Int J Cerebrovasc Dis(国际脑血管病杂志)，2006，14(2)：81-83. [9] YANG Z Y，LIU G Q. Effect of p-glycoprotein inhibitor combinations on drug efflux from rat brain microvessel endothelial cells[J]. Pharmazie，2004，59(12)：952-956. [10] JIN X H，BAO S Y. P-Glycoprotein and Blood-Brain Barrier[J]. Int J Cerebrovasc Dis(国际脑血管病杂志)，2006，14(4)：282-285. [11] LOCKMAN P R，MUMPER R J，KHAN M A，et al. Nanoparticle technology for drug delivery across the blood-brain barrier[J]. Drug Dev Ind Pharm，2002，28(1)：1-13. [12] LOCKMAN P R. Nanoparticle surface charges alter blood-brain barrier integrity and permeability[J]. J Drug Target，2004，12(9-10)：635-641. [13] SILVA G A. Nanotechnology approaches for drug and small molecule delivery across the blood brain barrier[J]，Surg Neurol 2007，67(2)：113-116. [14] LU W，ZHANG Y，TAN Y Z，et al. Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery[J]. J Controlled Release，2005，107(3)：428-448. [15] XING X Q，TAO T，CHEN Q H. Recent advances of drug delivery systems across blood-brain barrier[J]. Chin New Drugs J(中国新药杂志)，2002，11 (7)：519-523. [16] LIU-SNYDER P，WEBSTER T J. Designing drug-delivery systems for the nervous system using nanotechnology：opportunities and challenges[J]. Expert Rev Med Devices，2006，3(6)：683-687. [17] KOZIARA J M，LOCKMAN P R，ALLEN D D，et al. In situ blood-brain barrier transport of nanoparticles[J]. Pharm Res，2003，20(11)：1772-1778. [18] JAIN K K. Use of nanoparticles for drug delivery in glioblastoma multiforme[J]. Expert Rev Neurother，2007，7(4)：363-372. [19] KUO Y C，CHEN H H. Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylate-sulfopropylme- thacrylate on the permeability of zidovudine and lamivudine across the in vitro blood-brain barrier[J]. Int J Pharm，2006，327(1-2)：160-169. [20] LOHBACH C，NEUMANN D，LEHR C M，et al. Human vascular endothelial cells in primary cell culture for the evaluation of nanoparticle bioadhesion[J]. J Nanosci Nanotechnol，2006，6(9)：3303-3309. [21] GARCIA-GARCIA E，GIL S，ANDRIEUX K，et al. A methodology to study intracellular distribution of nanoparticles in brain endothelial cells[J]. Int J Pharm，2005，298(2)：310-314. [22] HANABE W，MAEDA T，FUKAZAWA Y, et al. P-glycoprotein ATPase activating effect of opioid analgesics and their P-glycoprotein-dependent antinociception in mice[J]. Pharmacol Biochem Behav，2006，85(6)：629-636. [23] KREUTER J，RAMGE P，PETROV V，et al. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles[J]. Pharm Res，2003，20(3)：409-416. [24] KIM H R，GIL S，ANDRIEUX K，et al. Low-density lipoprotein receptor-mediated endocytosis of PEGylated nanoparticles in rat brain endothelial cells[J]. Cell Mol Life Sci，2007，64(3)：356-364. [25] KREUTER J，HEKMATARA T，DREIS S，et al. Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain[J]. J Controlled Release，2007，118(1)：54-58. [26] NIKANJAM M，BLAKELY E A，BJORNSTAD K A，et al. Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme [J]. Int J Pharm，2007，328(1)：86-94. [27] PETRI B，BOOTZ A，KHALANSKY A，et al. Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles：revisiting the role of surfactants[J]. J Controlled Release，2007，117(1)：51-58. [28] KIM H R，ANDRIEUX K，GIL S，et al.Translocation of poly(ethylene glycol-co-hexadecyl)cyanoacrylate nanoparticles into rat brain endothelial cells：role of apolipoproteins in receptor-mediated endocytosis[J]. Biomacromolecules，2007，8(3)：793-799. [29] KRATZER I，WERNIG K，PANZENBOECK U，et al. Apolipoprotein A-I coating of protamine-oligonucleotide nanoparticles increases particle uptake and transcytosis in an in vitro model of the blood-brain barrier[J]. J Controlled Release，2007，17(3)：301-311.